Latest Breaking News On - Company phase - Page 1 : vimarsana.com

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

11.06.2024 - Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, ...

Champion Iron : Financial Document - MarketScreener

Management's Discussion and Analysis For the Year Ended March 31, 2024 TSX: CIA - ASX: CIA ...

North Peak Resources : MD&A for the Three months ended March 31, 2024

North Peak Resources Ltd. Management's Discussion and Analysis For the Three Months Ended March 31, 2024 Expressed in Canadian Dollars ...

Surge Energy Inc. announces non-core asset sales; commencement of Phase 2 return of capital framework; normal course issuer bid; base dividend increase; sparky crude oil discovery; and updated 2024 guidance

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting

Ocugen to Present at BIO International Convention 2024

Aummune's Poster at ASCO 2024 to Highlight Ongoing Phase 1 Trial for AM003

Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

Bio-Path Holdings To Present Data At 2024 European Hematology Association Congress

Vir Biotechnology, Inc.: Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The